EIGR insider filings
Eiger BioPharmaceuticals, Inc. — 14 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-11-02. Screen EIGR transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for EIGR between 2026-07-10 and 2026-10-08. The table below lists the most recent filings on record.
Recent insider filings — Eiger BioPharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-11-02 | 4 | KAYNE RICHARD A — 10% owner | Purchase (P): 11,987 @ $0.26 · Purchase (P): 12,345 @ $0.26 · Purchase (P): 130,509 @ $0.24 · Purchase (P): 100,000 @ $0.28 · Purchase (P): 23,398 @ $0.30 | EDGAR |
| 2023-11-02 | 4 | KAWAS LEEN — 10% owner | Purchase (P): 11,987 @ $0.26 · Purchase (P): 12,345 @ $0.26 | EDGAR |
| 2023-09-05 | 4 | Choong Ingrid — Chief Business Officer | Grant/award (A): 54,000 (derivative) @ $0 | EDGAR |
| 2023-07-06 | 4 | Apelian David — CEO, Director | Grant/award (A): 750,000 (derivative) @ $0 | EDGAR |
| 2023-05-02 | 4 | Vollins James — General Counsel | Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2023-03-21 | 4 | Mayer Eldon C. III — Ex VP & Chief Commerc. Officer | Sale (S): 2,520 @ $1.07 · Sale (S): 1,875 @ $1.07 | EDGAR |
| 2023-03-03 | 4 | Sachdev Amit — Director | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2023-03-03 | 4 | Loh Evan — Director | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2023-03-03 | 4 | Murray Christine — Director | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2023-03-03 | 4 | Glenn Jeffrey S — Director | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2023-03-03 | 4 | Sablich Kim — Director | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2023-03-03 | 4 | Kelly-Croswell Lisa — Director | Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2023-03-03 | 4 | Mayer Eldon C. III — Ex VP & Chief Commerc. Officer | Grant/award (A): 98,000 (derivative) @ $0 | EDGAR |
| 2023-03-03 | 4 | Dietz Thomas John — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Eiger BioPharmaceuticals, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2024-10-01 | 8-K | 1.03 — Bankruptcy or Receivership 3.03 — Material Modification to Rights of Security Holders 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-09-09 | 8-K | 1.03 — Bankruptcy or Receivership 3.03 — Material Modification to Rights of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-09-04 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets | EDGAR |
| 2024-09-03 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-08-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-08-01 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-07-16 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-07-10 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets | EDGAR |
| 2024-07-01 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-06-21 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=EIGR returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →